Navigation Links
First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII

VIENNA, Feb. 24, 2012 /PRNewswire/ -- CSL Behring has announced that the first patient has been screened in its recombinant coagulation single-chain factor VIII (rFVIII) trial, part of the AFFINITY clinical trial program. The CSL Behring rFVIII, called 'rVIII-SingleChain', is a novel molecule being studied for the treatment of hemophilia A. It is being developed by CSL Behring, in collaboration with its parent company, CSL Limited (ASX: CSL).

"CSL is advancing at a very encouraging rate with our recombinant coagulation factor development program," said Dr. Andrew Cuthbertson, Chief Scientist CSL Limited. "Our ongoing commitment to providing safe and effective therapies to help improve the lives of those affected by hemophilia A and other rare bleeding disorders is being fulfilled with each milestone we reach. Our recombinant coagulation single-chain factor VIII molecule is showing strong promise. We look forward with excitement to seeing results of the phase I/III study in coming months."

About the AFFINITY Phase I/III Study
The Phase I/III study is an open-label, multicenter trial that examines the crossover safety, efficacy and pharmacokinetics of recombinant coagulation single-chain factor VIII compared with recombinant human antihemophilic factor VIII (octocog alpha). 

In Part 1 of the study, subjects will receive a single infusion of 50 IU/kg of octocog alpha followed by a single infusion of 50 IU/kg. In Parts 2 and 3 of the study, subjects will receive infusions of rVIII-SingleChain to prevent and treat bleeding (if required), at a dose and frequency determined by their study doctor (based on the subject's underlying bleeding phenotype). More information about the study design can be found at  

Recombinant single-chain factor VIII consists of two linked protein chains – a heavy one and a light one. Under certain conditions, these chains can dissociate, resulting in the formation of separated, or "dissociated," rFVIII chains. The CSL Behring rVIII-SingleChain uses a strong, covalent bond that connects the light and heavy chains, thereby creating a single chain rFVIII.

In-house studies have shown that the molecular integrity of rVIII-SingleChain is significantly increased using the single-chain design, resulting in a homogenous product that is more stable than currently available FVIII products. In addition, in-vitro studies have shown that rVIII-SingleChain demonstrates a very strong affinity for von Willebrand factor, resulting in a faster and more efficient binding to VWF. The FVIII/VWF complex plays an important role in the physiological activity and clearance of FVIII and has been shown to have an influence on the presentation of FVIII to the immune system.

The research leading to the initiation of the studies that CSL Behring is now conducting is the result of collaboration across the CSL Behring research sites in Marburg, Germany, in King of Prussia, USA, and at laboratories operated by CSL Limited in Melbourne, Australia.

About Hemophilia
Hemophilia is a congenital bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. In nearly all cases, it affects only males. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. Hemophilia A affects approximately 1 in 5,000 to 10,000 people. Hemophilia B affects approximately 1 in 25,000 to 50,000 people. The recommended treatment for patients who are factor deficient is to treat by replacement factor therapy. A complication in some patients is the development of inhibitory antibodies (inhibitors) to FVIII or FIX which renders replacement therapy ineffective. This can occur in up to 25 percent of hemophilia A patients and around 5 percent of hemophilia B patients. One treatment option for these patients is recombinant activated factor VII (called a bypassing agent) that can be used to achieve hemostasis without the need for factor VIII or IX.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide. CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX:CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Announces First Implants of TELIGEN® Implantable Defibrillator in China
2. Boston Scientific Receives Industrys First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients
3. Accelitech to Open the First CyberKnife Cancer Center Within the City of Chicago
4. The Wisconsin Heart Hospital Becomes the Worlds First to Use the Leonardo 3D Vision™ System
5. Quest Diagnostics Offers Industry-First 30-Day Ambulatory EHR Implementation Guarantee for Hospitals and IDNs
6. MIT Receives First ARRONAX Shipment, Launching Strontium-82 Validation Project
7. Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
8. OnSiteRx® Launches First for Arizona: Automated Drug Dispensing in Nursing Home
9. Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
10. GHX Acquires Beep N Track to Accelerate Delivery of Healthcare Industrys First Implantable Device Supply Chain Solution
11. Perrigo Announces the Launch of Loratadine-D 12 Store Brand Labels -- the First Store Brand Launch That Compares to Claritin-D® 12
Post Your Comments:
(Date:11/24/2015)... Avery Biomedical Devices (ABD), manufacturer of the ... appointment of Anders Jonzon , MD; Ph.D. as ... Dr. Jonzon is a Physiologist and consultant ... University, Uppsala and Children,s Hospital, Karolinska, Stockholm, ... at the Cardiovascular Institute (UCSF). His research has covered ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
(Date:11/24/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that ... Education and Human Resources will be presenting in the upcoming ... Plan Strategies for a Dynamic Market" on Dec. 1, 2015. ... consultant with the Cambridge Advisory Group, where she leads their ... The webinar will discuss the rapid growth of oral oncolytics, ...
Breaking Medicine Technology:
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Dr. Rodney E. Willey , has ... new venture, Koala Center for Sleep Disorders, provides treatment for snoring and sleep apnea ... have opened a Koala Center for Sleep Disorders in the US, one of four in ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... and Healthy Aging Program have announced their endorsement of the Medical Fitness ... Health Fitness is proud to have the MFN as one of our endorsed ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Autism Speaks, the ... global movement driven by social media and the generosity of people around the world. ... their social media networks to give – and share the personal stories behind those ...
(Date:11/24/2015)... Miami, FL (PRWEB) , ... November 24, 2015 ... ... manufacturer and engineer of patented products, announces Innovative Blending, a household invention that ... go. , "The Juice & Smoothie Bars market is worth $2 billion," says ...
(Date:11/24/2015)... ... November 24, 2015 , ... Robert Yeager CEO of PharmMD, has ... past year there have been multiple breakthroughs and challenges as healthcare reform moves out ... enabled their customers and partners to stay ahead of the curve by breaking down ...
Breaking Medicine News(10 mins):